Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Proactive Investors" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Proactive Investors for you to read. Along with our medical data and news we also list Proactive Investors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Proactive Investors Companies for you to search.
Analysts said that the next few years for the FTSE 250-online grocer would be about “delivering results and validating the economics rather than signing new partnerships"
Horlicks might not be big business in the UK anymore, but it is India, where hundreds of thousands of kids drink it every day for breakfast
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain."
Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), tells Proactive's Andrew Scott they've completed a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for their new antibiotic Iclaprim. Lumsden says upon acceptance of the filing of the NDA by the FDA, Iclaprim will receive priority review - a review period of six months instead of the st...
DS Smith said it is confident on the outlook for the year ahead with volume growth momentum seen continuing
The restraining order, handed down by the US District Court for the District of New Jersey, will remain in place pending a hearing on the preliminary injunction motion filed by Indivior last Friday
Its drug therapy imetelstat is used to treat lower-risk myelodysplastic syndrome, a type of blood cancer
Morleys supplies ingredients to major retailers and several consumer food brands and has spent the last six months developing a range of muesli products which contain SlimBiome
Zelda Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) executive chairman Harry Karelis tells Proactive Investors the medical cannabis researcher's latest news. Initial results from a paediatric brain cancer study being conducted with the Telethon Kids Institute in Perth have validated that two chemicals naturally occurring in the cannabis plant, THC and CBD, each have some anti-cancer effects. Zelda ...
Cannabis! Crptocurrencies! The Daily CryptoCann Report is where we take some time to focus on both areas.
The Grammy-award winner is working on a blockchain project for musicians
'We remain cautiously bullish on the sector, albeit with a stock-picking approach,' writes Hartaj Singh
The analysts thumped the table for AndexXa forecasting peak sales of US$1.25bn in 2029
Sales of generic methadone and naltrexone, a drug used to treat alcoholism, slowed in fiscal 2018
The proposed changes to iron deficiency anemia drug Feraheme go beyond what the company proposed in June 2014
The panel wasn’t convinced that Elevair would have any effect on those taking it, or that the possible benefits outweighed the risks
Researchers have been assessing its potential use in Beta-Thalassemia - a blood disorder which reduces the production of haemoglobin
Researchers have been assessing its potential use in Beta-Thalassemia - a blood disorder reduces the production of haemoglobin
ValiRx released the positive results of a phase II trial of its lead drug earlier this year and it is now looking for a partner to help take VAL401 through a phase III study and into the market
Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), talks Proactive's Andrew Scott through the latest developments across the business. Looking ahead, Smith says: ''The priorities for us without doubt are third party deals on both sides - be they licensing deals, supply deals etc on the reagents and diagnostics side and we've got a really full pipeline of high quality partner...
The two food delivery giants are clearly in a turf war
Western Union says no to adding a cryptocurrency transfer service
The City broker said the group’s results for the 2018 financial year had confirmed progress had been made as well as being a “significant” surprise
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company's non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval. The company recently went public...
The AIM-listed bio-pharma company said Iclaprim had received Qualified Infectious Disease Product designation from the FDA together with Fast Track Designation